fatnews.com Fatnews Bitchute Channel Link Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Belviq (lorcaserin) increases risk of heart attack, cardiovascular death and non-fatal stroke 2-fold


    Posted by .(JavaScript must be enabled to view this email address)
    Saturday, November 01, 2014 1:08 pm Email this article

    Belviq (lorcaserin), a weight loss drug, in one study was associated with a “twofold increased rate of cardiovascular death, non-fatal myocardial infarction [heart attack] or non-fatal stroke” according to a paper looking at side effects of the drug written by James DiNicolantonio, PharmD and others.

    “In BLOOM-diabetes mellitus (DM), there was also an increase in adverse events related to ischaemic heart disease with lorcaserin [Belviq, a weight loss drug,] versus placebo (0.6% vs 0.4%, respectively) with a twofold increased rate of cardiovascular death, non-fatal myocardial infarction [heart attack] or non-fatal stroke,” notes the paper.

    Reference

    DiNicolantonio JJ, Chatterjee S, O’Keefe JH, and Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart, 2014; 1(1): http://openheart.bmj.com/content/1/1/e000173.full.

    Author’s Contact Info

    James J. DiNicolantonio, PharmD
    Associate Editor BMJ Open Heart
    Cardiovascular Research Scientist
    Saint Luke’s Mid America Heart Institute
    http://www.saintlukeshealthsystem.org/dinicolantonio
    https://www.researchgate.net/profile/James_Dinicolantonio
    https://twitter.com/jjdinicol
    .(JavaScript must be enabled to view this email address)


    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.